HCM
IMRX icon

Heights Capital Management’s Immuneering IMRX Stock Holding History

Heights Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$140K – 202
2025
Q3 		$140K Buy
+20,000
New +$104K 0.04% 117

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Heights Capital Management's IMRX Position: Q4 2025 in Review

Heights Capital Management sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 20,000 shares — an estimated $140K sold.

Heights Capital Management first reported a position in IMRX in Q3 2025 and held it in 1 quarter. The position peaked at $140K in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

  • Heights Capital Management reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
  • Heights Capital Management sold 20,000 Immuneering shares in Q4 2025, an estimated $140K.
  • Heights Capital Management first reported a position in Immuneering in Q3 2025 and held it in 1 quarter.
  • Heights Capital Management's Immuneering position peaked at $140K in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Heights Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.